NGAL Recombinant Antibody, Cy5 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bsm-61425r-cy5-100uL |
| Product Name | NGAL Recombinant Antibody, Cy5 Conjugated |
| Applications |
WB
IF
|
| Reactivity | Human |
| Specifications | |
| Conjugation | Cy5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human NGAL |
| Clonality | Recombinant |
| Isotype | IgG |
| Concentration | Lot dependent |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 3934 |
| Swiss Prot | P80188 |
| Subcellular location | Secreted |
| Synonyms | LCN2; 24p3; MSFI; NGAL; Lipocalin-2; p25; Siderocalin; SV40 induced 24P3 protein; Uterocalin. |
| Background | Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF | |
Frequently asked questions
Which applications is NGAL Recombinant Antibody, Cy5 Conjugated (bsm-61425R-Cy5) validated for, and at what dilution?
bsm-61425R-Cy5 is validated for WB (1:300-5000); IF. These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does NGAL Recombinant Antibody, Cy5 Conjugated (bsm-61425R-Cy5) react with?
Tested reactivity: Human.
How should bsm-61425R-Cy5 be stored?
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise NGAL Recombinant Antibody, Cy5 Conjugated (bsm-61425R-Cy5)?
KLH conjugated synthetic peptide derived from human NGAL
What are the excitation and emission wavelengths of the Cy5 conjugate (bsm-61425R-Cy5)?
Cy5 on bsm-61425R-Cy5: excitation / emission 625,650nm/670nm.
